Could Cytori Therapeutics Inc (NASDAQ:CYTX) Go Up After Its Newest Short Interest Report?

April 25, 2018 - By Michael Collier

Cytori Therapeutics, Inc. (NASDAQ:CYTX) Logo

The stock of Cytori Therapeutics Inc (NASDAQ:CYTX) registered an increase of 19.76% in short interest. CYTX’s total short interest was 3.04 million shares in April as published by FINRA. Its up 19.76% from 2.53 million shares, reported previously. With 573,100 shares average volume, it will take short sellers 5 days to cover their CYTX’s short positions. The short interest to Cytori Therapeutics Inc’s float is 9%.

The stock increased 0.35% or $0.001 during the last trading session, reaching $0.286. About 243,830 shares traded. Cytori Therapeutics, Inc. (NASDAQ:CYTX) has declined 82.57% since April 25, 2017 and is downtrending. It has underperformed by 94.12% the S&P500.

Cytori Therapeutics, Inc. develops cellular therapeutics for specific diseases and medical conditions. The company has market cap of $17.62 million. The firm primarily provides Cytori Cell Therapy, which is in Phase III pivotal clinical trial for the treatment of impaired hand function in scleroderma. It currently has negative earnings. It also offers Celution System devices, proprietary enzymes, and sterile consumable sets that are used at the point-of-therapeutic application or at an off-site processing center; and StemSource cell and tissue banking systems, as well as surgical accessories and instruments.

Cytori Therapeutics, Inc. (NASDAQ:CYTX) Ratings Coverage

Among 3 analysts covering Cytori Therap (NASDAQ:CYTX), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Cytori Therap had 3 analyst reports since November 7, 2017 according to SRatingsIntel. Laidlaw maintained Cytori Therapeutics, Inc. (NASDAQ:CYTX) rating on Thursday, February 22. Laidlaw has “Buy” rating and $1.65 target. As per Friday, March 9, the company rating was maintained by Maxim Group.

Cytori Therapeutics, Inc. (NASDAQ:CYTX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: